Advertisement

Table of Contents

Masters of Immunology

Cancer Immunology at the Crossroads: Experimental Immunotherapies

Commentary

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures | AuthorChoice
    HLA-Binding Properties of Tumor Neoepitopes in Humans
    Edward F. Fritsch, Mohini Rajasagi, Patrick A. Ott, Vladimir Brusic, Nir Hacohen and Catherine J. Wu
    Cancer Immunol Res June 1 2014 2 (6) 522-529; DOI:10.1158/2326-6066.CIR-13-0227

    Tumor neoantigens are common T-cell targets in humans with regressing or sometimes long-term stable disease. Fritsch and colleagues analyzed their predicted HLA-binding properties, and herein show that they provide important guidance for neoepitope selection for personalized cancer vaccines.

  • Cancer Immunology Miniatures
    Tumor MHC Class I Expression Improves the Prognostic Value of T-cell Density in Resected Colorectal Liver Metastases
    Simon Turcotte, Steven C. Katz, Jinru Shia, William R. Jarnagin, T. Peter Kingham, Peter J. Allen, Yuman Fong, Michael I. D'Angelica and Ronald P. DeMatteo
    Cancer Immunol Res June 1 2014 2 (6) 530-537; DOI:10.1158/2326-6066.CIR-13-0180

    Using a tissue microarray of liver metastases from 158 patients with colorectal cancer, Turcotte and colleagues show that high MHC class I expression with dense intratumoral T-cell infiltration identifies patients with favorable outcomes independent of conventional prognostic factors.

Research Articles

  • Research Articles
    Immune-Escape Markers in Relation to Clinical Outcome of Advanced Melanoma Patients Following Immunotherapy
    Esther P.M. Tjin, Gabrielle Krebbers, Kimberley J. Meijlink, Willeke van de Kasteele, Efraim H. Rosenberg, Joyce Sanders, Petra M. Nederlof, Bart A. van de Wiel, John B.A.G. Haanen, Cornelis J.M. Melief, Florry A. Vyth-Dreese and Rosalie M. Luiten
    Cancer Immunol Res June 1 2014 2 (6) 538-546; DOI:10.1158/2326-6066.CIR-13-0097

    Tjin and colleagues analyzed a large panel of immune markers in patients with stage IV advanced melanoma prior to autologous tumor-cell vaccination and report that high density of intratumoral CD4+ and CD8+ T cells with elevated granzyme B expression is correlated with favorable clinical outcome.

  • Research Articles
    Cancer–Testis Antigen 7 Expression and Immune Responses Following Allogeneic Stem Cell Transplantation for Multiple Myeloma
    Eleanor M. Tyler, Achim A. Jungbluth, Sacha Gnjatic, Richard J. O'Reilly and Guenther Koehne
    Cancer Immunol Res June 1 2014 2 (6) 547-558; DOI:10.1158/2326-6066.CIR-13-0174

    Tyler and colleagues show that cancer–testis antigen 7 (CT7) protein expression in the bone marrow and CT7-specific T-cell responses in blood are associated with the disease course of patients with multiple myeloma following allogeneic stem cell transplantation, supporting immunotherapeutic targeting of CT7 as a treatment for multiple myeloma.

  • Research Articles
    The Dose-Dependent Tumor Targeting of Antibody–IFNγ Fusion Proteins Reveals an Unexpected Receptor-Trapping Mechanism In Vivo
    Teresa Hemmerle and Dario Neri
    Cancer Immunol Res June 1 2014 2 (6) 559-567; DOI:10.1158/2326-6066.CIR-13-0182

    Hemmerle and Neri show in three syngeneic murine tumor models that immunocytokine F8–IFNγ targets tumoral fibronectin, recruits and activates leukocytes, and needs relatively high doses to localize on tumors, and that its antitumor activity is potentiated by combination with F8-IL4 without additional toxicities.

  • Research Articles
    TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells
    Megumi Narusawa, Hiroyuki Inoue, Chika Sakamoto, Yumiko Matsumura, Atsushi Takahashi, Tomoko Inoue, Ayumi Watanabe, Shohei Miyamoto, Yoshie Miura, Yasuki Hijikata, Yoshihiro Tanaka, Makoto Inoue, Koichi Takayama, Toshihiko Okazaki, Mamoru Hasegawa, Yoichi Nakanishi and Kenzaburo Tani
    Cancer Immunol Res June 1 2014 2 (6) 568-580; DOI:10.1158/2326-6066.CIR-13-0143

    Narusawa and colleagues found that type 1 IFNs and plasmacytoid dendritic cells in the tumor-draining lymph nodes mediate GM-CSF–induced antitumor immunity in immunocompetent mice, and they report that the synthetic TLR7 ligand imiquimod could overcome tolerance and enhance autologous GM-CSF antitumor effects.

  • Research Articles
    Antitumor Effects of Cisplatin Combined with Tecemotide Immunotherapy in a Human MUC1 Transgenic Lung Cancer Mouse Model
    Chiao-Jung Kao, Gregory T. Wurz, Arta M. Monjazeb, Daniel P. Vang, Timothy B. Cadman, Stephen M. Griffey, Michael Wolf and Michael W. DeGregorio
    Cancer Immunol Res June 1 2014 2 (6) 581-589; DOI:10.1158/2326-6066.CIR-13-0205

    Kao and colleagues report that concurrent cisplatin/tecemotide therapy induced additive reduction in lung tumor foci associated with a Th1 immune response. They further suggest that localized lung radiotherapy may enhance the CTL-driven antitumor activity of tecemotide.

Back to top
Cancer Immunology Research: 2 (6)
June 2014
Volume 2, Issue 6

Sign up for alerts

Jump to

Advertisement